Table 3
VIP trial results by absence or presence of classic neovascular lesions
| Outcome at 2 years (primary outcome of loss of at least 15 letters of VA) | VIP PDT group | VIP Placebo | VIP RR (95% CI) | TAP PDT group | TAP Placebo | TAP RR (95% CI) |
|---|---|---|---|---|---|---|
| *As reported in published paper. | ||||||
| †Mostly >0% and <50% according to table of participants. | ||||||
| ‡Not reported; calculated by subtraction. | ||||||
| §Minimally classic TAP trial results. | ||||||
| Whole trial* | 121/225 | 76/114 | 0.81 (0.68 to 0.96) | 189/402 | 129/207 | 0.75 (0.65 to 0.88) |
| No classic* | 91/166 | 63/92 | 0.80 (0.66 to 0.97) | 18/41 | 14/20 | 0.63 (0.40 to 0.98) |
| >0% classic† | 30/59‡ | 13/22‡ | 0.86 (0.56 to 1.32) | 106/202§ | 58/104§ | 0.94 (0.76 to 1.17) § |
